Liu D, Wancho A, Sapan C; International Conference on AIDS.

Int Conf AIDS. 1993 Jun 6-11; 9: 553 (abstract no. PO-B42-2510).

Abbott Laboratories, Abbott Park, IL.

OBJECTIVE: To evaluate the window of detectability seroconversion panels for three FDA licensed HIV EIAs. Two of the assay used conventional Goat anti-Human HRPO technology and one employed a unique antigen HRPO conjugate. METHOD: 21 different commercial seroconversion panels, from NABI and BBI, comprising 175 total samples, were tested using the Abbott HIVAB HIV-1/HIV-2 rDNA EIA, the Abbott HIVAB HIV-1 EIA, and the Genetic Systems HIV-1/2 EIA. RESULTS: The Abbott HIVAB HIV-1/HIV-2 rDNA EIA detected 121 of the 175 samples, the Abbott HIVAB HIV-1 EIA detected 110 of 175 samples, and the Genetic Systems HIV-1/HIV-2 EIA detected 90 of 175 samples. The Abbott HIVAB HIV-1/HIV-2 rDNA EIA detected 8 of 21 panels earlier than the Abbott HIVAB HIV-1 EIA by an average of 5.1 days. The Abbott HAVAB HIV-1/HIV-2 rDNA EIA detected 15 of 21 panels earlier than the Genetic Systems HIV-1/HIV-2 EIA by an average of 8.9 days. The Abbott HIVAB HIV-1 EIA detected 13 of 21 panels earlier than the Genetic Systems HIV-1/HIV-2 EIA by an average of 7.2 days. CONCLUSION: In this study, the Abbott HIV-1/HIV-2 rDNA Eia was the most sensitive assay for seroconversion sensitivity. The HIVAB HIV-1/HIV-2 rDNA EIA detected on average 8.9 days and as much as 17 days prior to the Genetic Systems HIV-1/HIV-2 EIA. This was theoretically attributable to the unique antigen conjugate assay format. This format is capable of detecting multiple classes of immunoglobulin (IgG or IgM) effectively narrowing the window between infection and detection by EIA. This study also demonstrates the effectiveness of recombinant technology for HIV EIAs. The HIVAB HIV-1/HIV-2 rDNA EIA had the best seroconversion detectability and it is also the only assay, in this study, that used recombinant protein technology.

Publication Types:

• Meeting Abstracts

Keywords:

• Acquired Immunodeficiency Syndrome
• Animals
• Equine Infectious Anemia
• HIV Infections
• HIV Seropositivity
• HIV-1
• HIV-2
• Humans
• Immunoenzyme Techniques

Other ID:

• 93336159

UI: 102205537

From Meeting Abstracts